# Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

> **NCT02474355** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 3017 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **PROCEDURE:** T790M+ Testing
- **PROCEDURE:** Baseline Visit Blood & Urine Testing
- **PROCEDURE:** Baseline ECG
- **PROCEDURE:** Visual Slit-Lamp Testing
- **DRUG:** AZD9291 Dosing

## Key facts

- **NCT ID:** NCT02474355
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-18
- **Primary completion:** 2019-04-18
- **Final completion:** 2019-04-18
- **Target enrollment:** 3017 (ACTUAL)
- **Last updated:** 2021-11-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02474355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02474355, "Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02474355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*